NEW YORK, NY--(Marketwired - Jan 15, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) could hold the key to making what is a miracle drug for some, into an even more powerful miracle drug for many. The company entered the medical marijuana industry with its wholly-owned subsidiary, Cannabis Biosciences, Inc., for the purpose of developing and testing a new Phytofare™ botanical extract derived from cannabis. Researchers may quickly find that Plandaí's "hydrodynamic sheering" process could deliver an extract that is more friendly to the human body than seen in the industry to date.

Plandaí, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, will develop an extract called Phytofare™ Phyto-cannabinoid Complex as its initial offering in the medical marijuana space. Plandaí uses a proprietary method of extracting phytochemicals from plants to develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

The company says this new extract will share a similar extraction process to its other Phytofare™ products. The system, called "hydrodynamic sheering," uses a combination of heat, pressure and hydro-cavitation to unzip living plant molecules and active antioxidants. These released molecules are then reduced into mainly nano-particle size where the antioxidant isomers are realigned making them more compatible with human tissues.

The first product which will come to market using this unique process is Phytofare™ Catechin Complex, which is derived from and includes the entire array of catechins found in Green Tea. Plandaí's new cannabis derived extract is expected to demonstrate the same high levels of bioavailability and purity as its other Phytofare™ products, and this is good news for patients who are looking to medical marijuana for relief and in other cases a cure.

About Stock Market Media Group

SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. For more information and to read disclaimers and disclosures:

This article is the opinion of Stock Market Media Group and was written based upon publicly available information. Plandaí Biotechnology, Inc. hasn't endorsed or compensated Stock Market Media Group for this article.

Contact Information:

Stock Market Media Group